Advancing role of melatonin in the treatment of neuropsychiatric disorders  by Mahmood, Danish et al.
Review Article
Advancing role of melatonin in the treatment of
neuropsychiatric disorders
Danish Mahmood *, Bala Yauri Muhammad, Mahfoudh Alghani,
Jamir Anwar, Nasra el-Lebban, Mohammad Haider
Department of Pharmacology & Toxicology Unaizah College of Pharmacy, Qassim University, Saudi Arabia
A R T I C L E I N F O
Article history:
Received 17 February 2016
Received in revised form 1 June
2016
Accepted 2 July 2016
Available online 9 July 2016
A B S T R A C T
Melatonin is a pineal neurohormone whose secretion is influenced by circadian changes
of 24 hour night and day cycle. Over the recent past, several studies have highlighted the
ubiquitous influence of the circadian timing in almost all the physiologic functions.An altered/
deficient sleep–wake cycle has been correlated with physiological imbalances which are linked
to the development of various disorders, viz depression, anxiety, psychosis, attention defi-
cits, sleep deprivation and others. Melatonin and its oxidation products, viz cyclic
3-hydroxymelatonin, N1-acetyl-N2-formyl-5-methoxykinuramine and N1-acetyl-5-
methoxykinuramine possess excellent antioxidant properties. Melatonin’s beneficial
neuroprotective properties are mostly attributed to excellent free radical scavenging prop-
erties. A gathering body of evidence has shown that besides strong antioxidant activities,
melatonin is a pleiotropic regulator molecule which orchestrates multiple functions through
all the three melatonin receptors, i.e. MT1, MT2, and MT3. For example, MT2 receptor ago-
nistic activity is attributed to neuroprotective, hypnotic and anxiolytic properties while MT1
and MT2 agonistic activity is associated with the clinical efficacy of agomelatine. The third
melatonin receptor has been identified as quinone reductase (QR) 2, an enzyme involved
in detoxification. MT3 agonist has been linked to strong hypotensive effects in preclinical
study.
In conclusion, the gathering body of evidence both from preclinical and clinical litera-
tures suggests strong antioxidant activities and diverse pleiotropic mechanisms of melatonin
for potential neuroprotective role in diverse neuropsychiatric disorders. However, there is
still a lack of melatonergic ligands with high selectivity and specificity to precisely target
any particular neuropsychiatric disorders for which limited therapeutic options are cur-
rently available clinically.
© 2016 Mansoura University. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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1. Introduction
Melatonin (N-acetyl-5-methoxytryptamine) is regarded as a
human time-keeping machine and is also referred to as the
hormone of darkness. It performs clock and calendar func-
tions to make the human body adapt to diurnal variation which
influences the 24-h rhythms in human physiology and behav-
iors. In 1958, Lerner and colleagues isolated and chemically
characterized melatonin in the mammalian pinealocytes [1].
Lately, because of the involvement of melatonin in many physi-
ological and behavioral functions such as sleep–wake cycle,
hormonal secretion, thermoregulation, and other physiologic
events, melatonin is now called pleiotropic neurohormone [2].
Melatonin has also been reported to regulate feeding behav-
ior, energy metabolism, free radical scavenging, immunity,
maintenance of vasculature, inflammation, cancer cell prolif-
eration, reproduction, growth and development, and aging [3].
1.1. Physiological response of melatonin and
suprachiasmatic nucleus
Suprachiasmatic nucleus or nuclei (SCN), a tiny region located
in the anterior part of the hypothalamus and situated di-
rectly above the optic chiasm, is called as master circadian-
pacemaker or the central body clock of mammals responsible
for controlling circadian rhythms. The activity of SCN is gov-
erned by the expression of clock genes. Signals from SCN travel
along multiple-synaptic pathways, involving complex
intrahypothalamic connection, to control circadian rhythm via
the regulation of melatonin secretion [4]. Light activates pho-
tosensitive,melanopsin-containing, retinal ganglion cells, which
are sensitive to short-wavelength visible light and communi-
cate the information directly to SCN via the retinohypothalamic
tract (RHT). Neuronal axons in RHT release the glutamate and
pituitary adenylate cyclase activating polypeptide (PCACP), me-
diating clock gene expression in SCN. Inhibitory projections (γ-
aminobutyric neurons) in SCN send a direct inhibitory projection
to paraventricular nucleus (PVN) of the hypothalamus. Neu-
ronal cells in PVN activate preganglionic neurons of
intermediolateral cell column which control the sympathetic
output to the pineal gland regulating the secretion of mela-
tonin by the pineal gland [5–7]. Melatonin is primarily produced
by the pineal gland from amino acid tryptophan. Small amounts
of melatonin is also produced in gut, Harderian gland, bone
marrow, epithelial hair follicles, skin, retina, salivary glands,
platelets, lymphocytes and developing brain but the physi-
ological significance of melatonin from these extrapineal sites,
except retina, is still a matter of debate. Norepinephrine (NE)
is the major neurotransmitter involved in the regulation of
arylalkylamine N-acetyltransferase (AANAT), the rate limit-
ing enzyme in melatonin synthesis. There are two pathways
involved in the synthesis and release of melatonin which are
stimulated by NE. The first is β1-adrenergic/cyclic adenosine
monophosphate (cAMP)/protein kinase A (PKA) activation, and
the second involves α1-adrenergic/calcium [Ca2+] pathways. Ac-
tivation of β1 receptors increases cAMP concentration,
intracellularly, leading to the activation of cAMP-dependent PKA.
Both elevated cAMP levels and PKA activation are critical for
stimulation of AANAT. Secondly, the activation of α1 recep-
tors leads to increases in the intracellular calcium concentration
([Ca2+]i) by the release of calcium ions from intracellular stores
followed by Ca2+ influx into the pinealocytes [8]. Amino acid
tryptophan, the precursor for melatonin synthesis, is actively
up taken into the pinealocytes, hydroxylated and decarbox-
ylated to serotonin. During the day, serotonin in pinealocytes
is stored, and remains unavailable to enzymes (monoamine
oxidase and melatonin-forming enzymes) which would oth-
erwise act on it. With the onset of darkness, postganglionic
sympathetic outflow to the pineal increases which causes the
release of NE and the subsequent activation of adrenergic re-
ceptors on pinealocytes causes stored serotonin to become
accessible for intracellular metabolism. Melatonin is pro-
duced by the metabolism of serotonin into in two steps which
are catalyzed by AANAT or serotonin N-acetyltransferase
(SNAT) and hydroxyindole-O-methyltransferase (HIOMT) or
acetylserotonin N-methyltransferase (ASMT). N-acetylation of
serotonin by AANAT produces N-acetylserotonin (NAS) and
O-methylation of NAS by HIOMT, eventually, produces mela-
tonin (Fig. 1) [8,9].
1.1.1. Melatonin receptors
Melatoninmediates physiological effects via MT1 andMT2 mela-
tonin receptors which are specific G-protein coupled receptors.
MT1 receptor is reported as sensitive to the pertussis toxin while
MT2 melatonin receptor is reported as sensitive to the cholera
toxin. MT1 and MT2 receptors are expressed in the central
nervous system (CNS), including, hippocampus, ventral teg-
mental areas, and SCN.Additionally,MT1 receptor also expresses
in retina, ovary, testis, mammary gland, coronary arteries, gall
bladder, aorta, liver, kidney, skin and the cardiovascular system
and MT2 melatonin receptor in retina and human pituitary
gland [8,10]. Melatonin mediated intracellular signaling in-
volves modification of the activities of adenylyl cyclase (AC),
phospholipase C (PLC), guanylylcyclase (GC), cyclic guanosine
monophosphate (cGMP) as well as calcium and potassium chan-
nels [8,10,11]. Physiological responses associated with MT1
receptor activation include the modulation of neuronal firing,
arterial vasoconstriction, cell-proliferation in cancer cells, re-
productive and metabolic functions [10], and MT2 receptor
associated physiological responses include the phase shift cir-
cadian rhythms of neuronal firing in the SCN, inhibition of
dopamine release in retina and leukocyte rolling in arterial beds,
induction of vasodilatation, and enhancement of immune re-
sponses [11]. Two additional proteins were also reported as
melatonin receptors or melatonin receptor modulators. A third
melatonin receptor, MT3, was also identified which binds to
quinone reductase 2 (QR2). GPR50 is another melatonin-
related protein having 45% similarity to human MT1 and MT2
receptors. GPR50 does not directly bind to melatonin but it in-
fluences the binding of melatonin to MT1 receptor [12]. A
deletion of GPR50 has been genetically linked to psychiatric
disorders such as bipolar disorder and major depression [13].
1.1.2. Melatonin metabolism
Metabolism of melatonin (Fig. 2) primarily takes place in hepatic
cells with the aid of cytochrome P450, family 1, subfamily A,
polypeptide 1 (CYP1A1) and cytochrome P450, family 1, sub-
family B, polypeptide 1 (CYP1B1). However, it was reported that
CYP1A2 and, to some extent, CYP2C19, are primarily respon-
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sible for the plasma clearance of melatonin by the hepatic
cells. In humans, melatonin is principally metabolized to
6-hydroxymelatonin, which is further conjugated with sulfate
and excreted in urine [14].) In addition, extrahepatic metabo-
lism of melatonin into 6-hydroxymelatonin occurs by CYP1B1
which has a prominent extrahepatic distribution and does not
show significant expression in hepatic cells.
The common metabolic pathways of melatonin [I] involve
firstly, 6-hydroxylation to 6-hydroxymelatonin [II], which is
sulfated to 6-sulfatoxymelatonin [V], and secondly, by
O-demethylation to NAS [III], which is further conjugated
to its sulfate [VI] and its glucuronide [VII] and excreted
in urine. A minor pathway involves deacetylation to
5-methoxytryptamine [IV], which can be further metabolized
to a range of minor metabolites, including pinoline, bufoten-
ine, N,N-dimethyltryptamine, and serotonin, which acts as
precursor to melatonin production [I] in the serotonin–
melatonin cycle [14].Other importantmetabolites resulting from
melatonin oxidation include cyclic 3-hydroxymelatonin, N1-
acetyl-N2-formyl-5-methoxykinuramine (AFMK) andN1-acetyl-
Fig. 1 – Diagrammatic depiction of melatonin synthesis and regulation. AANT: arylalkylamine N-acetyltransferase; cAMP:
cyclic adenosine monophosphate; HIOMT: hydroxyindole-O-methyltransferase; PKA: protein kinase A.
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Fig. 2 – Diagrammatic illustration of the common metabolic pathways of melatonin and its oxidative products. AFMK: N1-
acetyl-N2-formyl-5-methoxykinuramine; AMK: N1-acetyl-5-methoxykinuramine.
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5-methoxykinuramine (AMK).AFMK is formed by pyrrole-ring
cleavage,bymyeloperoxidase, indoleamine 2,3-dioxygenase and
various non-enzymatic oxidants [14].
2. Melatonin in various neuropsychiatric
disorders
Melatonin received wide attention as it has been observed that
patients suffering from neuropsychiatric disorders usually have
abnormal melatonin secretion and many neuropsychiatric dis-
orders including anxiety, depression, insomnia, narcolepsy,
epilepsy, schizophrenia, Parkinson’s disease (PD), and Alzheim-
er’s disease (AD) have a disturbed circadian rhythm [15–17].
A recent review on melatonin use has indicated MT2 melato-
nin receptor’s involvement in the pathophysiology of sleep
disorders, anxiety, depression, AD and pain, and has also re-
ported that selective MT2 receptor agonists have hypnotic and
anxiolytic properties [18], and selective MT2 receptor agonists
are being discovered for possible treatment of mental disor-
ders for which limited drug therapies are currently available
[18]. Melatonin potential to treat several neuropsychiatric dis-
eases could be due to its pleiotropic biological effect, some of
which are mediated via activation of MT receptors and others
are due to strong antioxidant activities which protect nuclear
and mitochondrial DNA from reactive oxidative species. AFMK
and AMK are melatonin by-products having excellent radical
scavenging activity [19]. AMK has been reported to scavenge
reactive oxygen and nitrogen species, and is a mitochondrial
modulator, downregulator of cyclooxygenase-2, inhibitor of
cyclooxygenase, neuronal and inducible NO synthases, and is
a better hydroxyl radicals scavenger thanmelatonin [20]. Diverse
therapeutic role of melatonin has been attributed to its ability
to induce apoptosis and arrest cell cycle, antimetastatic and
antiangiogenic, anti-inflammatory, and antioxidant effects.Also,
melatonin has been reported to detoxify xenobiotic and en-
dobiotic compounds via the up-regulation of Nrf2 (a protein
which controls the expression of antioxidant proteins) and re-
cently reported as an inhibitor of proteasome.The involvement
in sleep initiation, vasomotor control, adrenal function,
antiexcitatory actions, immunomodulation including anti-
inflammatory properties, antioxidant actions, and energy
metabolism influencing mitochondrial electron flux and mi-
tochondrial biogenesis contribute to the neuroprotection by
melatonin [21].
2.1. Anxiety and panic disorder
Several studies have reported a promising therapeutic role of
melatonin in anxiety and panic disorders [22–26].A recent study
has shown that melatonin could increase the beneficial effect
of buspirone against several parameters of anxiety including
the immobilization of stress-induced anxiety-like behavioral
and oxidative damage in mice [22]. Melatonin administration
during the night-time chronically ameliorated the stress-
induced behavioral disturbances, particularly the cognitive
dysfunctions and depressive phenotypes in mice [23]. Treat-
ment with melatonin and agomelatine alone was ineffective
as anxiolytic agent butwhen combined the efficacy of anxiolytic
drugs was potentiated [24]. The beneficial effect of melatonin
premedication in surgery to reduce anxiety and fear of surgery
has been reported in clinical studies [25–27]. In patients un-
dergoing cataract surgery, premedication with sublingual
melatonin reduced the anxiety scores and provided excellent
operating conditions for doctors [25]. Preoperative use ofmela-
toninwas reported topossess similar efficacy to benzodiazepines
in reducing preoperative anxiety with minimal action on psy-
chomotor performance and sleep–wake cycle.Thus,melatonin
could serve as an alternative to benzodiazepines in the
remediation of preoperative anxietywith no significant adverse
effects in short-term use [26,27]. Another recent study has in-
dicated that premedication with oral or sublingual melatonin
could be equally effective in reducing preoperative anxiety in
adults similar to the standard treatment withmidazolam [26].
Moreover,melatoninwas also reported to have an opioid sparing
effect and also reduced intraocular pressure. Hence, melato-
nin could also be used to prevent postoperative delirium [27].
A review of the published data has reported the clinical effi-
cacy of agomelatine in generalized anxiety disorder. However,
trials evaluating agomelatine efficacy in generalized anxiety
disorder are currently few and require several randomized,
placebo-controlled studies on larger samples and in the treat-
ment of other anxiety disorders, such as panic disorder, social
anxiety disorder, obsessive–compulsive disorder and post-
traumatic stress disorder to solicit therapeutic benefit of
melatonin in generalized anxiety disorder [28]. Recently, Patel
and Kurdi [29], in a clinical study, compared the effects of oral
melatonin and oral midazolam in preoperative anxiety, cog-
nitive, and psychomotor functions. Melatonin given orally at
0.4 mg/kg showed comparable anxiolytic activity to that of oral
midazolam without the impairment of general cognitive and
psychomotor functions as observed with the treatment of
midazolam [29].
2.2. Migraine
Migraine is primarily a headache disorder which is character-
ized by recurrent episodes of headache associated with
gastrointestinal, neurologic, and autonomic symptoms. Some
evidence is present to show that the melatonergic system could
possibly play an important role in the pathogenesis of mi-
graine. Previously, in 2011, Tabeeva et al. [30] reported that
agomelatine could possibly be used as a preventive treat-
ment for migraine. Agomelatine has been reported as a novel
treatment option for migraine prophylaxis due to its specific
mechanism of action and similarity to melatonin. In 2013,
Guglielmo et al. [31] reported two cases of patients with mi-
graine being successfully treated with agomelatine; one patient
presented with comorbid depression, whereas the other had
no comorbidities. Recently, Plasencia-García et al. [32] pre-
sented a case series of 6 female patients who visited outpatient
clinics for Recurrent Major Depressive Disorder [American Psy-
chiatric Association’s Diagnostic and Statistical Manual of
Mental Disorders IVText Revision (DSM-IV-TR)] and all hadmod-
erate depressive episode [meanMontgomery–Asberg Depression
Rating Scale (MADRS) score of 26.66 ± 3.72] at the time of as-
sessment. All patients were suffering from migraine since 20
years with nearly 4 attacks per month (based on the diagnos-
tic criteria of the International Headache Society, 2004), and
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a pain intensity of over 9 as per Visual Analogue Scale (VAS).
All patients were receiving amitriptyline, beta-blockers and
topiramate as prophylactic treatment for headaches, which was
stopped due to lack of response or adverse effects. Initially
agomelatine was administered at a dose of 25 mg for depres-
sive episode which was increased to 50 mg/24 hours in 4
patients due to lack of remission after 8 weeks of treatment.
Remission in depressive episode (MADRS 1.16 ± 1.16) with con-
siderable reduction in frequency of migraine attack (from 4 to
<1 attacks/month) and intensity of the attacks (from 9 to 2) was
noted after 4 months.The patients reported a considerable re-
duction in frequency of attacks from the first month of
treatment. Guglielmo et al. attributed the improvement to treat-
ment with agomelatine in all these cases since the patients
were non-responders to past treatment with other antidepres-
sants for migraine episodes despite remission of the symptoms
of depression. Hence, it may be assumed that efficacy of
agomelatine could be related to the synergic action between
melatonin agonism and 5-HT2C antagonism. However, further
studies are needed to clarify the precise pathophysiological and
neurochemical mechanisms involved in the specific
antimigraine response [31].
2.3. Epilepsy
Treatment of epilepsy continues to pose a challenge in spite
of the availability of advanced medications because firstly, a
significant proportion of patients showdrug resistance [33], and
secondly, poor adherence and drug interactions associatedwith
multi-drug prescription and the fear of worsening seizures by
some of the prescribedmedications lead to an incomplete cure
fromepilepsy.An increasing body of literature reports thatmela-
tonin might possibly play an important role in the treatment
of pharmacoresistant and other refractory types of epilepsy
[34,35]. Melatonin has been reported to easily cross the blood–
brain barrier and modulate electrical activities of neurons by
reducing glutamatergic and enhancing γ-aminobutyric (GABA)
neurotransmission. In animal studies, melatonin administra-
tion was reported to inhibit audiogenic and electrical seizures,
as well as reduce pentylenetetrazole-induced convulsions in-
cluding convulsion produced by pilocarpine, L-cysteine and
kainate [34].The by-products ofmelatonin, kynurenic acid,have
been reported to have endogenous anticonvulsant and also free
radical scavenging and antioxidant activities. In a study on the
effect of a high concentration of melatonin on PC12 cells in-
vestigated norepinephrine release and melatonin’s role on
excitatory postsynaptic potential in rat hippocampal slices re-
ported inhibitory effect ofmelatoninonneurotransmitter release
which is possibly by blocking voltage-sensitive Ca2+ channels.
In pilocarpine-induced epilepsy model, melatonin adminis-
tration chronically reduced a number of spontaneous seizures
and cell damage in animals having status epilepticus [35]. In
one of the studies,Moeizi et al. [36] explored the interaction of
melatonin and agmatine (a biogenic amine with anticonvul-
sant properties) on seizure susceptibility in pentylenetetrazole-
induced clonic seizure model in mouse and also studied
melatonin receptors involvement using luzindole, a MT1/2 re-
ceptor antagonist, and prazosin, a MT3 receptor antagonist.
Luzindole (2.5 mg/kg) significantly prevented the anticonvul-
sant effect of melatonin (40 and 80 mg/kg) but not prazosin
(0.5 mg/kg), indicating that MT1/2 receptor could be involved in
the anticonvulsant effect of melatonin.The anticonvulsant ef-
ficacy of melatonin, both effective dose (80 mg/kg) and non-
effective dose (20 mg/kg), was significantly enhanced by the
concurrent administration of agmatine (5 mg/kg). This sug-
gested an additive effect of melatonin in decreasing
pentylenetetrazole-induced seizure threshold in mice [36]. A
study investigated the effect of melatonin treatment (10 mg/
kg/day,diluted indrinkingwater,8weeks) during epileptogenesis
and on the consequences of a kainate induced status epilepticus
inmurinemodels [37].The findings of the study suggested that
melatonin delayed the appearance of spontaneous recurrent
seizures and decreased their frequency only during the treat-
ment period. In epileptic rats, melatonin treatment showed
positive effect on the behavioral alterations associated with
hyperactivity, depression-like behavior during the light phase,
and deficits in hippocampus-dependent working memory.
Further, the treatment of melatonin reduced the neuronal
damage in CA1 region of hippocampus and piriform cortex, and
improvedhippocampal serotonin level in epileptic rats.However,
long-term treatment ofmelatonin following status epilepticus
could not prevent the development of epileptogenesis but was
able to reduce some of the deleterious effects which occurred
during the chronic epileptic state [25,37].Also, in a similar study
involving kainate model of temporal lobe epilepsy, treatment
of melatonin during the epileptogenesis prevented harmful
effects of status epilepticus in spontaneously hypertensive rats.
Also,melatonin treatment was able to reduce the neuronal on-
slaught, specifically in CA1 region of hippocampus and piriform
cortex and decreased hippocampal serotonin levels both in the
control and spontaneously hypertensive epileptic rats. Mela-
tonin treatment chronically post status epilepticus significantly
improved seizure activities and neuronal loss but epilepsy-
induced behavioral abnormalities were unaltered in
spontaneously hypertensive rats [38].
Melatonin reduced some of the changes which occurred
during the chronic epileptic state. Another study reported po-
tentiation of phenobarbital efficacy bymelatonin administration
[39].The probable mechanisms for antiepileptic efficacy of mela-
tonin, as reported from animal studies, are inhibition of
neurotransmitter release (possibly by blocking voltage-sensitive
Ca2+ channels) and perhaps mediation via nitric oxide/L-
arginine pathway [35,40]. Thus, melatonin could exert
neuroprotective effects by attenuating status epilepticus-
induced post-lesion and decrease the number of seizures [41].
In clinical studies, complete disappearance of seizures, reduced
seizure latency [42], improvement in seizures severity [43], and
control of convulsive episodes have been reported with mela-
tonin therapy [44]. In 2012, a pilot study by Goldberg et al. [45]
reported melatonin therapy to be safe and effective in de-
creasing daytime seizure frequency in patients with intractable
epilepsy. The adjunct use of melatonin in the seizure man-
agement has been suggested. A clinical study has reported low
serum concentration of melatonin in children with epilepsy
or complex febrile seizure and the treatment of exogenous
melatonin improved febrile seizure and epilepsy in children
[46]; however a recent study has indicated against melatonin
use in children who are suffering from convulsive disorders
[47]. Based on literature from both animal and clinical studies,
it may be concluded that melatonin has anticonvulsant effi-
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cacy; however, at the moment there is no clear-cut evidence
to justify its any imminent use in epilepsy.
2.4. Depression and mood disorders
Disturbed sleep and circadian rhythms is a prominent feature
of depression and altered melatonin secretion has been ob-
served in major depression [48]. In shift workers, an abnormal
melatonin secretion has been reported to cause several psy-
chiatric diseases including depression. A preclinical study has
reported reduction in the immobility time (an indicator of an-
tidepressant activity) with the treatment of melatonin and NAS
in the mouse tail suspension test [49]. It was reported that QR2/
MT3 agonist, 5-methoxycarbonylamino-N-acetyltryptamine,
decreased, while the QR2/MT3 antagonist, prazosin, increased
the duration of immobility in the tail suspension test in a dose-
dependent manner. The modulation of QR2/MT3 receptor has
been correlated with the antidepressant effects of melato-
nin. Thus, novel antidepressant agents may be developed via
MT3 receptor agonistic approach [49].
One of the studies had evaluated the possible beneficial
action of chronic night-time melatonin treatment against
chronic mild stress (CMS) induced behavioral impairments. In
this study, it was noted that stress exposed mice had reduced
weight gain, hedonic deficit, cognitive deficits and decreased
mobility in the behavioral despair test. These mice also dis-
played less anxiety. Administration of melatonin night-time,
chronically, had considerably improved the stress-induced be-
havioral disturbances, viz. the cognitive dysfunction and
depressive phenotypes. In conclusion, findings suggested that
there was a mitigating role of melatonin against CMS-induced
behavioral changes, including the cognitive dysfunctions, thus
reaffirming its potential role as an antidepressant [23]. In 2011,
Quera-Salva et al. [50] reported that antidepressant agents with
intrinsic chronobiotic properties could offer a novel ap-
proach to the treatment of depression.A clinical study involving
14 depressed patients (5: major depression and 9: bipolar dis-
order) and 14 matched controls have shown increased MT1
receptors in the SCN. The study suggests that increased MT1
receptor expression may be involved in the circadian disor-
ders and could contribute to the efficacy of melatonin or its
agonists in the depression [51]. Seasonal affective disorders and
mood disturbances which result from circadian malfunction
could be treated by chronobiotic drugs, chronotherapy or bright
light therapy, and melatonin and its agonists possess
chronobiotic effects which could reset the circadian system
[50,52]. A recent systematic review and meta-analysis did not
find clear evidence of a therapeutic or prophylactic effect of
melatonin against depression or depressive symptoms [26].
However, a randomized, double-blind, placebo-controlled trial
investigating the effect of a 6 mg/day dose of melatonin given
for three months post-surgery to patients with breast cancer
having symptoms of depression, anxiety, sleep disorder, cog-
nitive dysfunction and fatigue has shown reduced depressive
symptoms, and increased sleep efficiency perioperatively and
total sleep time postoperatively [48]. Agomelatine has been de-
veloped as a novel and clinically effective antidepressant drug
with melatonergic (MT1/MT2) agonist and 5-HT2C receptor an-
tagonist properties and has been approved for the treatment
of major depressive disorder in adults by the European Medi-
cines Agency.The efficacy of agomelatine remains questionable
despite evidence showing superiority of over placebo and se-
lected antidepressant agents because it remains to be
established that the magnitude of effect size is clinically sig-
nificant and sample characteristics are relevant to the general
patient population with major depressive disorder [53]. A syn-
ergistic interaction between melatonergic and serotonergic
receptors in the agomelatine effects in restoring circadian
rhythms and relieving depressive symptoms has been re-
ported by several studies.Agomelatine does not have an affinity
for histaminergic, adrenergic or dopaminergic receptors, sug-
gesting that it may be free of side effects displayed by traditional
antidepressant agents [54,55]. In a comprehensive meta-
analysis by Taylor et al. [56], agomelatine has been reported
as moderately more effective than placebo. The effect size for
agomelatine compared with placebo was found to be similar
to that of other marketed antidepressants, and showed similar
efficacy to standard antidepressant in comparator controlled
trials. Agomelatine has been reported a justifiable treatment
option in patients who are unable to tolerate adverse effects
of standard antidepressants or in whom standard drugs are
contraindicated. Agomelatine’s demonstrable acute efficacy is
intriguing given its unique pharmacological mode of action and
good tolerability.Thus, further researches are warranted to dis-
cover newer compounds possessing melatonergic activity and
to confirm the efficacy of agomelatine in depression [56]. An-
hedonia is known as a condition in which the capacity to
experience pleasure is totally or partially lost. Currently, there
is no definitive specific pharmacological approach to the treat-
ment of anhedonia in depression.The efficacy of agomelatine
on the dimension of anhedonia may be of particular impor-
tance in the treatment of major depressive disorder (MDD) with
anhedonic features. A clinical study which included depres-
sion parameters, e.g. depressive (Hamilton Depression Scale;
HAM-D) and anxious (Hamilton Anxiety Scale; HAM-A) symp-
toms, anhedonia (Snaith Hamilton Rating Scale; SHAPS), and
sleep quality (Leeds Sleep Evaluation Questionnaire; LSEQ)
showed significant improvements at all visits on the HAM-D,
HAM-A, SHAPS, and LSEQ with the treatment of agomelatine.
The study reported significantly greater efficacy on anhedo-
nia and similar antidepressant efficacy to the serotonin-
norepinephrine reuptake inhibitor, venlafaxine, in patients with
MDD in an 8-week treatment period. Preliminary findings have
described the efficacy of agomelatine in the treatment of an-
hedonia to be novel among antidepressant agents which are
currently available [57,58]. Another clinical study involving 28
depressed patients with bipolar disorder reported agomelatine,
25 mg/day, to be an effective and well-tolerated adjunct to
valproate/lithium for acute depression in BD-II [59].
In a review in 2013, De Berardis et al. [60] also highlighted
the efficacy of agomelatine MDD and anhedonia. They re-
ported appreciable reduction in SHAPS scores compared to
venlafaxine in anhedonia and similar efficacy to sertraline and
superior efficacy to venlafaxine and escitalopram in MDD treat-
ment with agomelatine. Agomelatine also fared well in side
effect and safety and acceptability profiles compared to current
medications. Agomelatine does not cause loss of libido com-
pared to venlafaxine and has better sexual acceptability than
paroxetine in healthy male volunteers. Further, fewer discon-
tinuation rates were reported for agomelatine for any cause
208 e g y p t i an j o u rna l o f b a s i c and a p p l i e d s c i e n c e s 3 ( 2 0 1 6 ) 2 0 3 – 2 1 8
than venlafaxine, sertraline and fluoxetine. Moreover, data
suggest that agomelatine was not associated with discontinu-
ation symptoms, even if this potential side effect warrants
further investigation, especially regarding long-term risks.The
incidence of relapse over six months was significantly lower
with agomelatine [60]. A recent clinical study has shown an
early impact of agomelatine treatment on sleep quality and
alertness at awakening, indicating that agomelatine could be
an effective antidepressant agent in the acute phase of MDD
[61]. Thus, it may be forecasted that the development of novel
melatonergic compounds would greatly advance the treat-
ment of depressive disorders.
2.5. Schizophrenia
Several studies have reported abnormal functioning of mela-
tonin in the pathophysiology of schizophrenia [62–64]. In the
past, alteration in melatonin secretion has been linked to pineal
calcification and pineal calcification size has been used to detect
the development and prognosis of schizophrenia. Melatonin
has been reported as a biomarker of schizophrenia which could
be used to identify the type of schizophrenia in patients [62].
MT1 and MT2 melatonin receptor has been reported as poten-
tial targets to improve psychotic symptoms [63]. Important link
between the promoter of the melatonin receptor 1A gene and
schizophrenic disorder has been reported and a higher change
in melatonin level is reported in monozygotic twins discor-
dant for schizophrenia [64]. Psychosis and dreaming, including
delusions, hallucinations, bizarre thinking and perceptual dis-
tortions, have many similarities, leading to the hypothesis that
SCN which regulates sleep and wakefulness could be in-
volved in the pathogenesis of schizophrenia [65]. It was
hypothesized that altered functioning of SCN could contrib-
ute to schizophrenia through several different, not necessarily
mutually exclusive, mechanisms, including “rapid eye move-
ment sleep (dream) rebound” phenomenon, damaged neuronal
pathways connecting SCN to the brain regions affected by
schizophrenia, and the SCN dysfunction induced dysregulation
of gene expression in different parts of the body, including the
brain [65]. Melatonin has been reported to prevent metabolic
side effects of antipsychotic agents. Olanzapine induced body
weight gain and visceral adiposity in rodents has been linked
to low plasma melatonin level, indicating possible use of mela-
tonin in the management of weight gain caused by
antipsychotic medications [66]. In schizophrenia, long-term
treatments with benzodiazepines often present with with-
drawal symptoms due to the development of dependence.
Melatonin has been reported to lower benzodiazepines intake
[67,68]. Controlled-release melatonin formulation may help
withdraw benzodiazepine therapy while maintaining good sleep
quality. A randomized clinical trial (NCT01431092) is evaluat-
ing the role of melatonin in long-term benzodiazepine
withdrawal treatment in schizophrenia patients and the result
is being awaited [69].
In 2014, Modabbernia et al. [70] reported a randomized
double-blind placebo-controlled study on 48 patients with first-
episode schizophrenia who were eligible for olanzapine
treatment.The patients were randomized to receive olanzapine
plus either melatonin 3 mg/day or matched placebo for eight
weeks. Anthropometric and metabolic parameters as well as
psychiatric symptoms using the Positive and Negative Syn-
drome Scale (PANSS) were assessed at baseline, week 4, and
week 8. Primary outcome measure was the change from base-
line in weight at week 8. Thirty-six patients were made to
have at least one post-baseline measurement. At week eight,
melatonin was associated with significantly less weight gain,
increase in waist circumference and triglyceride concentra-
tion than the placebo. Changes in cholesterol, insulin, and
blood sugar concentrations remained nearly the same between
the two groups. Patients in the melatonin group were re-
ported to have experienced significantly greater reduction in
their PANSS scores than the placebo group. No serious adverse
events were reported. The study findings showed that in pa-
tients treated with olanzapine, short-termmelatonin treatment
had attenuated weight gain, abdominal obesity, and
hypertriglyceridemia. It might also provide additional benefit
for treatment of psychosis. Thus, it was concluded that the
use of short term melatonin treatment in patients with first
episodes of schizophrenia who were on olanzapine treat-
ment could prevent the metabolic side-effects, viz weight gain,
abdominal obesity, and hypertriglyceridemia.
Agomelatine has been reported to possess favorable effi-
cacy in psychotic disorders [52]. Agomelatine, due to its 5HT2c
receptor antagonism, causes enhanced release of both nor-
epinephrine and dopamine at the fronto-cortical dopaminergic
and noradrenergic pathways, which indirectly stimulates the
release of brain-derived neurotrophic factor [58].
A recent study has reported compelling evidence of de-
creased peripheral BDNF levels in schizophrenia which was also
supported by the previously described reduced cerebral BDNF
expression in the psychotic disorders [71]. Thus, agomelatine
may be used in the treatment of symptoms associated with
schizophrenia. A 16-week, open-label, preliminary study in-
volving 20 outpatients (9 men and 11 women) with
schizophrenia was conducted to assess the efficacy of
agomelatine combination with clozapine in psychosis [72].The
patients used in this study were stable and receiving clozapine
monotherapy at the highest tolerable dose (mean dose 430 mg/
day) for at least one year. However, patients were regarded as
partial responders to clozapine due to the presence of re-
sidual symptoms and according to Brief Psychiatric Rating Scale
(BPRS) total scores of more than 25. Agomelatine augmenta-
tion of clozapine significantly improved PANSS as well as total
score and overall clinical symptoms (measured by BPRS) at week
8.At week 16, significant differences were noted in PANSS rating,
depressive symptoms (measured with the Calgary Depres-
sion Scale for Schizophrenia) and overall clinical symptoms.
At week 8, significant differences were noted in cognitive per-
formances only at Wisconsin Card Sorting Test (WCST)
“perseverative errors”, but, at week 16, agomelatine treat-
ment significantly improved performances on Stroop task and
increased improvement onWCST “perseverative errors”.At end-
point, 9 subjects (64.3%) of the 14 patients, who completed the
trial, responded to the coadministration of agomelatine (defined
as a reduction in PANSS total score >25% between the base-
line and follow-up ratings) and no patients reported worsening
in clinical symptoms compared to baseline [72]. Agomelatine–
clozapine combination was reported to be well tolerated.
However, most common adverse effects reported were gas-
trointestinal symptoms, headache and excessive sleepiness.
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There is a need for a bigger randomized blinded comparator
trial; involving a large sample size is required to draw any firm
conclusions. Thus, melatonin could be utilized as an add-on
medication to increase the efficacy of medications in schizo-
phrenia, decrease metabolic side effects and increase life-
expectancy of patients on long-term antipsychotic medication.
2.6. Obsessive–compulsive disorder
Obsessive–compulsive disorder (OCD), characterized as severe
persistent intrusive and disturbing thoughts (obsessions) and
repetitive stereotypic behaviors (compulsions), is a common
chronic neuropsychiatric disorder associated with marked dis-
tress and impairment of social and occupational functioning.
The manifestations of OCD are frequently associated with
anxiety or extreme fear [73].The etiopathology of OCD remains
poorly understood but patients often show hormonal imbal-
ance and disturbance in sleep phase, suggesting dysfunctional
circadian rhythms. 24 hour-secretion of melatonin was also
found to be reduced as compared to the healthy control sub-
jects and has been associated with the severity of the OCD
symptoms, particularly with obsessions. A dysfunction of nor-
adrenergic system followed by a dysregulation of melatonin
synthesis and secretion has been reported in OCD. A retro-
spective study has linked OCD with circadian rhythm sleep
disorder which is known as the delayed sleep phase syn-
drome (DSPS). Patients with OCD typically display DSPS which
causes excessive daytime sleepiness leading to disruption in
social and occupational functioning [73]. Patients with DSPS
usually go to bed and get up much later than normal.They are
unable to shift their sleep to an earlier time and, as a result,
suffer considerable disruption of social and occupational func-
tioning [74]. Administration of exogenous melatonin has been
reported to treat sleep disorders which increased the treat-
ment efficacy,mitigated relapse and protected against the onset
of co-morbid psychiatric illnesses in OCD patients [75]. There
is a close link between light and melatonin in the regulation
of sleep–wake cycle which suggests a possible role for treat-
ment with exogenous melatonin and/or light therapy in OCD
patients with DSPS. Thus, melatonin could be developed as a
pharmacological means for treating both OCD and DSPS [74].
In 2011, daRocha and Correa presented a case report of an adult
male patient with OCD who was unresponsive to clomip-
ramine treatment and also had problem with risperidone or
aripiprazole. Augmentation of the therapy with agomelatine
has been reported to improve patient’s condition possibly by
resynchronization of circadian-rhythm [76]. Further, clomip-
ramine and selective serotonin reuptake inhibitors are
established medications for OCD but they cause numerous
adverse effects, including weight gain and sexual dysfunc-
tions, severely impacting patient’s quality of life. Agomelatine
is reported to cause no clinically overt adverse effects such as
weight gain and sexual dysfunction. In another case report, a
22-year-old female student had severe OCD symptoms which
included washing and checking of hands and feet compul-
sively in response to contamination [77]. Her OCD caused
dermatitis in her hands and such cleaning/washing and check-
ing compulsions severely disrupted her social activities. She
was receiving medications which included fluvoxamine,
venlafaxine, lorazepam, and clomipramine and intake of these
medications developed several adverse effects. She was pre-
scribed agomelatine 25 mg/day at bedtime which significantly
improved her symptoms without any adverse effects after 2
weeks of therapy and subsequently dose was titrated to 50 mg/
day [77]. In yet another case study, agomelatine augmentation
of escitalopram therapy successfully treated a young female
patient suffering from severe treatment resistant OCD [78].
Another study, in 2013, also highlighted the potential
anticompulsive effect of agomelatine [79].Anticompulsive effect
of agomelatine is reported to be mediated via 5HT2C antago-
nism and MT1/2 agonism [79]. Thus, melatonergic agents could
be promising and may be developed for possible use in OCD
in conjunction with existing medications.
2.7. Parkinson’s disease
Parkinson’s disease (PD) is one of the most common
neurodegenerative disorders characterized by a progressive loss
of dopamine in the substantia nigra and striatum. It has been
reported that over 70% of dopaminergic neuronal death takes
place before appearance of the first symptoms, making it ex-
tremely difficult for an early diagnosis and effective treatment
of the disease [80,81]. Levodopa (L-dopa) has been used to restore
dopamine content which unfortunately provides only symp-
tomatic relief and also L-dopa intake is associated with certain
long-term pro-oxidant damage.The first evidence of a signifi-
cant relationship between Parkinson’s disease and melatonin
came from the finding that circulating melatonin concentra-
tion was low in PD patients due to diminished pineal activity
[82], and subsequently, due to the discovery of its potent an-
tioxidant properties, melatonin was successfully tested in
several in vivo and in vitro PD models. 1-Methyl-4-phenyl-
1,2,3,6-tetrahydopyridine (MPTP) is a neurotoxin responsible
for the PD syndrome which elicits an irreversible, severe
parkinsonian-like signs characterized by all the features ob-
served in PD, i.e., tremor, rigidity, slowness of movement, and
postural instability. In 2005, Mayo et al. [80] summarized all the
potential pathways involved in the neuroprotective actions of
melatonin in MPTP model of PD, which mimics most of the
symptoms of PD in humans. MPTP crosses the blood–brain
barrier and is converted by glial cells into 1-methyl-4-phenyl
pyridinium ion (MPP+) by monoamine oxidase B. MPP+ enters
into the dopaminergic terminals through the dopamine trans-
porter and accumulates in vesicles or in the mitochondria of
dopaminergic neurons and interferes with electron-transport
chain producing oxidative stress which eventually triggers apop-
tosis of dopaminergic neurons. The possible mechanisms
through which melatonin may elicit protective actions in-
cluded (1) potent antioxidant activities scavenging reactive
oxidative species, harmful to macromolecules and triggering
apoptosis; (2) antiapoptotic activities via the blockade of
apoptotic cascade; (3) activation of mitochondrial metabo-
lism; and (4) anti-inflammatory actions, by either blocking
microglia activation or inhibition of enzymes such as
cyclooxygenase 2 and inducible nitric oxide synthase which
produce proinflammatory mediators and nitric oxide, respec-
tively.Thus,melatonin blocks pro-apoptotic cascade at different
levels, preventing dopaminergic neuronal death which is re-
sponsible for causing parkinsonian signs. Cardiolipin is a
phospholipid located in inner mitochondrial membrane which
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is needed for several mitochondrial bioenergetic processes and
proper functioning of transport proteins. A change in cardio-
lipin structure and acyl chain composition causes mitochondria
to work abnormally under a variety of pathological dysfunc-
tions including PD. Melatonin has been reported to protect
mitochondrial membranes from oxidation-reduction damage
by stopping cardiolipin oxidation [83].
Alpha-synuclein (α-synuclein) is known to be involved in
the development of PD.Melatonin has been reported to prevent
α-synuclein fibril formation and destabilize the preformed
α-synuclein fibrils. It reduces α-synuclein-induced cytotoxic-
ity and thus prevents further development of PD symptoms
[84]. Melatonin was also shown to inhibit protofibril forma-
tion, oligomerization and secondary structure transitions.
Melatonin’s ameliorative effects were reported due primarily
to the inhibition of toxic polymers assembly and protection of
neurons from their toxic effects [84]. In a 2013 study, melato-
nin showedneuroprotective effects againstmutantα-synuclein-
induced injury in the substantia nigra [85]. In 2002,Antolín et al.
[86] developed a chronic experimentalmodel to study PD.They
administered a low-dose of MPTP, 15 mg/kg, body weight, for
35 days, to mice to induce nigral cell death.The mouse model
emulated the chronic condition of PD in humans. The re-
searchers observed that treatment ofmelatonin, 500 μg/kg, body
weight, prevented the neuron cell death and damage caused
by the long-term MPTP treatment. Antolín and his colleagues
proposed that melatonin may be a potential therapy agent to
prevent the disease and/or its progression [86]. Another study
in rats treated (via drinking water), chronically, with physi-
ological concentrations of melatonin (0.4 μg/ml and 4.0 μg/ml)
after partial lesioning with 6-hydroxydopamine (6-OHDA) in
the striatumhas also supported that physiological levels ofmela-
tonin have a protective role in parkinsonian neurodegeneration
in the nigrostriatal system [87].
A study involving unilateral 6-OHDA lesion rats and pa-
tients with PD has correlated the serum melatonin levels with
the severity of PD. The study found significantly higher levels
of serum melatonin than control groups during the morning
period, in both animal and human subjects with PD [88].
Another study reported that chronic administration of mela-
tonin orally improved 6-OHDA-induced neurotoxicity. The
animals treated with melatonin and L-dopa performed well in
various motor tasks without dyskinesia compared to animals
treated with L-DOPA alone [88]. In 2012, Gutierrez-Valdez et al.
[89], and in 2014, Yildirim et al. [90], showed other probable
mechanism of melatonin in PD. They reported that melato-
nin delayed the cellular and behavioral alterations produced
by 6-OHDA-induced neurotoxicity and prevented dopaminer-
gic neuronal death by increasing the levels of Bcl-2 protein (an
important anti-apoptotic protein) and decreasing the caspase-3
activity in PD [89,90]. In rotenone-induced animal model, ro-
tenone andmelatonin combination have shown neuroprotective
effects which have been linked to the inhibition of Omi and
Bax-induced autophagy [91,92]. In another study, prolonged
melatonin treatment after dopaminergic neuronal lesion did
not alter motor-function but produced antidepressant-like
effects in the forced swim-test and prevented rotenone-
induced dopamine reduction in the striatum, indicating
neuroprotective and antidepressant-like effects of melatonin
in PD [93]. Levodopa (L-DOPA) is an established medication used
to reduce the symptoms of PD, but it poses serious side effects
following chronic use. In 2013, Naskar et al. [94] reported that
melatonin potentiated the effects of low dose L-DOPA in
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced
experimental model of PD [94]. Treatment with L-dopa ame-
liorated motor performance in mice and significant
improvement of motor response was noted following treat-
ment with combined dose of L-dopa andmelatonin [95].A recent
study also confirmed that combination of melatonin and L-DOPA
reduced the doses of L-DOPA by 60%. Thus, addition of mela-
tonin might help to lower the doses of L-DOPA which may
reduce side effects caused by the chronic use of L-DOPA im-
proving clinical outcome [95]. In 2013, Zaitone et al. [96] reported
that combination of melatonin and L-DOPA also increased the
level of oxidative enzymes, e.g. lipid peroxidation, glutathi-
one and other antioxidant enzymes. Oxidative stress and free
radicals from mitochondrial impairment and dopamine me-
tabolism have been reported to play key roles in PD etiology.
Studies with melatonin have reported increased antioxidant
capacity of cells due to enhanced synthesis of antioxidant
enzymes including superoxide dismutase, glutathione peroxi-
dase, and glutathione reductase, and increased glutathione
levels. Melatonin is reported to maintain mitochondrial ho-
meostasis, reduce generation of oxidative species and protect
the production of mitochondrial adenosine triphosphate by
stimulating Complexes I and IV activities. Melatonin’s
neuroprotective activities have been tested successfully both
in in vivo and in vitro models of PD [97,98]. Moreover, melato-
nin is safe at higher doses and could readily cross the blood–
brain barrier [98]. The efficacy of melatonin in preventing
oxidative damage in either cultured neuronal cells or in the
brains of animals treated with various neurotoxic agents have
suggested that melatonin could be a novel neuroprotective drug
to be used in treatment of neurodegenerative disorders [99].
Melatonin production has been reported to decline in elderly
people, suggesting it to be one of the primary contributing
factors for development of age-associated neurodegenerative
diseases, and melatonin therapy treated chronic fatigue syn-
drome, improved sleep and quality of life in PD patients [100].
A case reported in 2013 by De Berardis et al. [60] reported im-
proved sleep efficiency and disappearance of intra-sleep
awakening by the treatment of agomelatine in PD patients with
depression.
Accumulating evidence have favored the use of melato-
nin in PD; however, there are some studies which have reported
no efficacy of melatonin in PD. In 1999,Willis and Armstrong
[101] reported that melatonin enhanced behavioral impair-
ment and dopamine degeneration and indicated that melatonin
receptor antagonist could serve to promote clinical recovery
in PD. They indicated that melatonin could not be a universal
remedy as suggested and may pose considerable problems in
neurological diseases characterized by dopamine degenera-
tion [101]. The finding of a study showed that chronic
administration of a high pharmacological dose of melatonin
was ineffective in protecting nigral dopaminergic neurons from
neurotoxic effects of MPTP [102]. The rat rotenone model has
been reported to reproduce many of the pathological fea-
tures of the human disease, including apomorphine-responsive
behavioral deficits, DA depletion, loss of striatal dopamine ter-
minals and nigral dopaminergic neurons, and α-synuclein/
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polyubiquitin-positive cytoplasmic inclusions reminiscent of
Lewy bodies. Therefore, this model is well-suited to examine
potential neuroprotective agents. In a review in 2008Willis [103]
reported that melatonin have a tendency to induce PD-like be-
havioral toxicity and presented abundant evidence to describe
PD as an endocrine disorder of melatonin hyperplasia. In 2010,
Tapias et al. [104] investigated the neuroprotective potential
of melatonin in the rotenone PD model.The researchers noted
that melatonin potentiated the striatal catecholamine deple-
tion, striatal terminal loss, and nigral dopaminergic neuron loss.
They indicted melatonin alone for causing the changes in the
striatal catecholamine content.Thus, the findings ofTapias et al.
suggested that melatonin is not neuroprotective in the rote-
nonemodel of PD and could even exacerbate neurodegeneration
[104]. Further, some clinical studies were also attempted which
have shown no therapeutic benefit with the use of melatonin
in PD.The data from one of the studies demonstrated that mela-
tonin had no significant protective effects against the long-
term MPTP induced depletion of the striatal dopamine and 3,4-
dihydroxyphenylacetic acid in the C57BL/6 mouse [105].
In 2005, Dowling et al. [106] conducted a multi-site double-
blind placebo-controlled cross-over trial involving 40 subjects
who completed a 10-week protocol. The study comprised of a
2-week screening period, 2-week treatment periods, and 1-week
washouts between treatments.Actigraphy and diaries were used
to assess nocturnal sleep. Epworth Sleepiness Scale (ESS), Stan-
ford Sleepiness Scale (SSS), and General Sleep Disturbance Scale
(GSDS) were used to measure daytime sleepiness and motor
function. Patients received melatonin or placebo 30 minutes
before bedtime. Using actigraphic measures, melatonin 50 mg
significantly increased nocturnal sleep time (10 minutes) versus
placebo (P < 0.05). Subjective outcomemeasures using the GSDS
showed thatmelatonin 5mg significantly improved overall sleep
quality compared to placebo (P < 0.05), but this was not the case
for melatonin 50 mg. Melatonin did not significantly improve
excessive daytime sleepiness versus placebo, according to the
ESS and Stanford Sleepiness Scale. Two patients had reported
minor adverse events with melatonin.The investigators noted
that although 50 mgmelatonin had significantly improved total
sleep time on actigraphy compared to 5 mg or placebo, the im-
provement was merely 10 min which might not be clinically
significant [106]. In 2007,Medeiros et al. [107] also failed to detect
anymotor effect of melatonin.Medeiros et al. conducted a clini-
cal study on 18 PD patients who were on Hoehn andYahr scale
from I to III. Patients were assessed for motor dysfunction using
Unified Parkinson’s Disease Rating Scale (UPDRS) II, III and IV
before receiving treatment. Pittsburgh Sleep Quality Index (PSQI)
and ESS were used to assess the subjective sleep quality and
daytime somnolence, respectively. All patients received full
polysomnography (PSG) test. Patients were randomly chosen
to receive melatonin (3 mg) or placebo one hour before bedtime
for four weeks, and test parameters were repeated at the end
of treatment. The initial finding of the study showed that 14
patients (70%) had PSQI rating of more than 6, indicating poor
quality sleep, and eight (40%) showed ESS rating of more than
10, suggesting excessive daytime sleepiness. PSG findings in-
dicated increased sleep latency, REM sleep without atonia, and
reduced sleep efficiency. The findings of the study suggested
that melatonin had significantly improved subjective quality
of sleep as evaluated by the PSQI index but because PSG ab-
normalities could not be reversed, melatonin was ineffective
in treating the motor dysfunction [107]. Thus, based on these
two studies, there is insufficient evidence on the efficacy of
melatonin at doses of 3 to 5 mg and 50 mg for the treatment
of insomnia in PD. Although melatonin at 3 to 5 mg had ac-
ceptable risk without specialized monitoring, there is an
insufficient evidence for melatonin at 50 mg.
2.8. Alzheimer’s disease
Alzheimer’s disease (AD) is known as an old-age senile
neurodegenerative disease which causes a progressive loss of
cognition, memory and other neurobehavioral disorders [108].
Melatonin level has been reported to be reduced to nearly half
in elderly patients with AD compared to the young control sub-
jects [109]. In the postmortem brain fromAD patients MT1 and
MT2 immunoreactivities were found to be affected compared
to age-matched controls. An increase in MT1 and a decrease
in MT2 immunoreactivity was noted in the hippocampus of AD
patients [110,111]. Accumulation of β-amyloid (Aβ) peptide in
the brain is known to be involved in the pathophysiology of
AD. Studies have reported antiamyloidogenic and anti-apoptotic
activities of melatonin in AD [112,113]. Melatonin has been re-
ported to inhibit Aβ fibril formation and also the production
of Aβ [112]. Reduction in the levels of melatonin precursors in-
cluding tryptophan and serotonin has been linked to the
appearance of AD symptoms in the elderly, indicating the in-
volvement of melatonin in the pathophysiology of AD [113].
Melatonin has been reported to upregulate the expression of
messenger ribonucleic acid (mRNA) for amyloid precursor
protein (APP) and the pretreatment of melatonin resulted in
a significant reduction of mRNA for APP in PC12 cells [114]. A
study involving the analyses of isolated-brain mitochondria
from mice indicated reduction in mitochondrial Aβ levels by
two- to fourfold in different brain regions, and a near com-
plete restoration of mitochondrial respiratory rates, membrane
potential, and ATP levels has been noted following the treat-
ment of melatonin [114]. In 2012, Garcia-Mesa et al. [115]
reported that administration of melatonin together with proper
physical exercise could act synergistically to prevent AD symp-
toms [115]. In a study,melatonin was found to protect neuronal
and astrocytic death induced by aggregated full length Aβ 1–40
and the fragments Aβ 25–40 and Aβ 1–28. Melatonin showed
no effect on the process of fibrillation of Aβ and did not alter
Aβ-induced calcium signaling in astrocytes, but significantly
reduced the rate of production of Aβ-induced reactive oxygen
species and also protected astrocytes against the mitochon-
drial depolarization.Thus, scavenging of reactive oxygen species
by melatonin was indicated to be the primary effect of mela-
tonin in protecting neurons and astrocytes against Aβ toxicity
[116].
2.9. Tardive dyskinesia
Tardive dyskinesia (TD) is one of themost disturbing side effects
of antipsychotic medications. The pathophysiology of TD has
been reported to involve dopamine receptor supersensitivity
and oxidative stress-induced neurotoxicity in the nigrostriatal
system. In a study, Shamir et al. suggested the use of mela-
tonin in the treatment ofTD because of its excellent antioxidant
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activities [117]. In addition, attenuation of dopaminergic ac-
tivity in the striatum has been reported with melatonin use
which may cause the release of dopamine from hypothala-
mus.This could potentially lead to prevention of the disabling
side effect of antipsychotic agents [117].A double-blind, placebo-
controlled, crossover study has reported the efficacy of
melatonin (10 mg/day for 6 weeks) in 22 patients with schizo-
phrenia and TD. The study showed a significant decrease in
the abnormal-involuntary-movement scale (AIMS) score com-
pared to placebo following treatment with melatonin (10 mg/
day for 6 weeks) [118]. Another randomized, double blind,
placebo controlled study also reported the efficacy of melato-
nin (20 mg/day) for a period of 12 weeks in 7 patients with TD,
and 6 PD patients receiving placebo.The AIMS score was used
to assess the severity of TD initially and after 4, 8 and 12 weeks
respectively. Psychiatric evaluation was also performed fol-
lowing the Brief Psychiatric Rating Scale.Two patients receiving
melatonin showed considerable improvement (>60%) in AIMS
score [119], indicating that melatonin could be beneficial in TD.
However, still several studies are needed to confirm melato-
nin efficacy and soliciting its use in TD.
2.10. Attention-deficit/hyperactivity disorder
Sleep disorders are the most common psychiatric disorders ob-
served in children with attention-deficit/hyperactivity disorder
(ADHD). A long-term study evaluated the safety and efficacy
of long-term (mean time up to 3.7 years) melatonin in chil-
dren with ADHD and chronic sleep onset insomnia using
questionnaires answered by parents of patients [120].The study
surveyed parents whose children were treated with melato-
nin on average, 3.7 years. The long-term melatonin treatment
was effective against sleep problems in 88% of the cases and
improved behavior andmood in 71% and 61%, respectively, with
no serious adverse effects [120].Two controlled studies further
evaluated the role of melatonin in sleep disorder treatment in
children with ADHD.The first study was a double-blind, placebo
controlled, 30-day crossover trial conducted on 27 stimulant-
treated children (6 to 14 years of age) with ADHD. Non-
responders to sleep-hygiene guidelines were treated with
melatonin (5 mg/day, 20 minutes before bedtime) or placebo.
Patients who were given melatonin experienced significant re-
duction in sleep-onset latency compared to those treated with
placebo. The best results were obtained when both sleep–
hygiene was taken care of with melatonin intervention [121].
The second study was also a randomized, double-blind, placebo-
controlled trial that recruited 105 medication-free children (6
to 12 years of age) with diagnosed ADHD and chronic sleep-
onset insomnia. Participants were treated with melatonin (3–
6 mg, body weight) or placebo for 4 weeks. Participants who
were treated with melatonin reported significant increase in
sleep-onset, total sleeping time in comparison with no sig-
nificant adverse effect on the behavior, cognition, or quality
of life [122]. Minor adverse effects noted with melatonin treat-
ment were similar to placebo in either of the two studies. A
review of clinical studies on efficacy and safety of melatonin
in sleep disorders in children with ADHD reported melatonin
to be well-tolerated and effective in pediatric patients [123].
A recent study has recommended that treatment with mela-
tonin in chronic sleep onset insomnia in ADHD should be best
reserved for children suffering from persistent insomnia. Mela-
tonin intakemay impact normal pubertal and endocrine system
development in children [124].
2.11. Autism
Autism or autism spectrum disorders (ASD) is a
neurodevelopmental disorder characterized by impaired social
interaction, verbal and non-verbal communication, and re-
stricted and repetitive behavior [125]. Children with a history
of developmental regression are reported to develop dis-
turbed sleep-pattern in comparison to children without
regression. The regulation of sleep in children with ASD has
remained poorly understood. Genetic anomaly related to mela-
tonin synthesis and altered modulation of the synaptic
transmission by melatonin which causes circadian abnormali-
ties could cause autism in children [126,127]. A bifurcation of
the sleep/wake cycle with increased sensitivity to external noise
and short-sleep duration which causes irregular sleep-onset
and wake-up times are also suggested in the pathogenesis of
ASD. In ASD, low levels of melatonin and melatonin metabo-
lite has been noted as compared to control subjects, and their
exogenous administration have shown improvement in sleep
parameters and daytime behavior, and minimized side effects
[128,129]. In 2014, Rossignol and Frye provided an evidence-
based exogenous use of melatonin for abnormal sleep
parameters in ASD [130]. Hyperserotonemia and deficit in mela-
tonin in 35–46% and 45–57%, respectively, have been reported
of ASD patients. Both hyperserotonemia and low melatonin
levels have been correlated with the disruption of serotonin–
NAS–melatonin pathway which was suggested to serve as a
useful biomarker for a characterization of a large group of ASD
patients [131]. One of the published literatures reported three
cases of autistic disorder which showed that nocturnal symp-
toms had improved with the use of ramelteon, a selective
melatonin receptor agonist. The Clinical Global Impression-
Improvement Scale for assessing insomnia and behavior
showed that 2 mg dose of ramelteon improved in two cases
and 8 mg dose of ramelteon in the third case, indicating that
ramelteon was effective not only for insomnia, but also effec-
tively reduced behavioral problems in patients with autistic
disorder [132]. Thus, the conclusion drawn from the past and
present published literatures indicates that melatonin could
be an effective, safe, and a well-tolerated option to treat sleep
disorders in children with ASD [133].
3. Downsides of melatonin use as novel
neuropsychatric agent
Uncontrolled use of apparently any innocuous chemical sub-
stance is associated with some kind of danger. The same may
also apply for melatonin use which has been largely reported
as safe. However, the absence of adverse effects in healthy sub-
jects taking melatonin for various reasons does not mean
complete safety, particularly in patients who are unwell [134].
Acute exogenous administration of melatonin has been re-
ported to cause sedation, fatigue, self-reported vigor and a
reduced body temperature in healthy subjects. It is said that
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the timing is critical for melatonin to be effective and if given
at wrong time for sleep disorders or jet lag, it may increase
daytime sleepiness and worsen mental performance. Drowsi-
ness and a small fall in body temperature are commonly
reported effects particularly after daytime administration when
endogenous concentrations of melatonin are low. Melatonin
use has been reported to cause headache, altered light adap-
tation, and loss of visual acuity and reduced vision which had
improved after stopping melatonin. Melatonin use was also as-
sociated with some cases of retinal damage. Melatonin
increased seizure activity in children with pre-existing neu-
rological disorders and a recurring convulsion was reported
upon continued use. Melatonin withdrawal upon chronic use
was associated with tardive dyskinesia and akathisia as mela-
tonin blocks dopamine receptors.These are some of the serious
conditions associated with melatonin use which have high
death rate and low recovery rate. Therefore, melatonin is rec-
ommended with caution in patients with organic brain damage.
In several depressed patients, it has causedmixed affective state
after taking melatonin. Confusion, hallucination, and para-
noia were also associated with melatonin use. Gynecomastia
has been attributed to melatonin. Increased blood glucose levels
have been noted in healthy individuals and in patients with
Parkinsonismwho tookmelatonin.Melatonin treatment chroni-
cally has been reported to cause withdrawal symptoms.
Unentrained sleep–wake cycle has been noted after melato-
nin was stopped. Involuntary movements of the lip and tongue,
restlessness and insomnia developed when melatonin was
abruptly withdrawn. Melatonin has been reported to interact
with antidepressants. It may cause drowsiness, dizziness and
acute psychosis if taken with fluoxetine, trazodone and
paroxetine. If taken with amitriptyline and chlordiazepoxide,
melatonin may cause lethargy, confusion, and disorienta-
tion. Overdose of melatonin may cause drowsiness, dizziness,
blurred vision and confusion in patients withMDD. Fluvoxamine
increases the systemic availability of oral melatonin prob-
ably by reducing first pass clearance [134].
4. Conclusion
Over the last decades, accumulating evidence from both ex-
perimental and clinical studies has highlighted immense
therapeutic potential of melatonin in several diseases includ-
ing CNS disorders. Neurons are highly susceptible to oxidative
stresses leading to lipid peroxidation and generation of reac-
tive oxygen/nitrogen species which are implicated in almost
all the neuropsychiatric and neurodegenerative disorders.Mela-
tonin and its metabolites, e.g. AFMK,AMK have been confirmed
to have an excellent antioxidant with powerful free radical scav-
enging properties, making it one of the most suitable novel
therapeutic agents to be tried in such disorders involving oxi-
dative stress. A gathering body of evidence suggests that
melatonin is a pleiotropic regulator molecule orchestrating
diverse physiological function and involves all the melatonin
receptors; however, precise pleiotropic mechanisms of mela-
tonin remain to fully be deciphered. Ramelteon and agomelatine
are two clinically successful melatonin compounds which elicit
hypnotic and chronobiotic efficacy via MT1 and MT2 receptor.
Altered circadian rhythm due to disturbed melatonin secre-
tion has been ascribed to development of several neurological
disorders and augmented lipid peroxidation. Agomelatine
therapy has been prescribed in depression associated insom-
nia, and ramelteon in chronic insomnia in non-psychiatric
patients. Selectivity and specificity are two important compo-
nents for the success of any novel compounds, and therefore,
development of selective and specific melatonergic com-
pounds are warranted to target brain disorders for which limited
therapeutic options are currently available, and hence, re-
searches involving melatonin in neuropsychiatric disorders is
very promising.
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